RCT-2100 is under development for the treatment of cystic fibrosis (CF). The therapeutic candidate is an mRNA, encoding cystic fibrosis transmembrane conductance regulator (CFTR). It is administered ...
Galicaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback